Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKY9GI)

• Drug Name: Activated recombinant FVII-albumin fusion protein Drug Info
• Synonyms: CSL-689; Activated recombinant FVII-albumin fusion protein (hemophilia); Activated recombinant FVII-albumin fusion protein (hemophilia), CSL Behring; RVIIa-FP (hemophilia), CSL Behring; Recombinant factor VIIa/human albumin fusion protein (hemophilia), CSL Behring

Indication

Disease Entry	ICD 11	Status	REF
Hemophilia	3B10.0	Phase 2/3	[1]

• Cross-matching ID: TTD Drug ID: DMKY9GI

Molecule-Related Drug Atlas

Drug(s) Targeting Coagulation factor VII (F7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Factor viia	DMZUW6P	Hemophilia	3B10.0	Approved	[3]
Vatreptacog alfa (activated)	DMANKTO	Bleeding disorder	GA20-GA21	Phase 3	[4]
BAX-817	DMB147A	Hemophilia	3B10.0	Phase 3	[5]
Recombinant factor VIIa PEGylated liposomal	DMY3TAD	Factor VII deficiency	3B14	Phase 1/2	[3]
F-7TG	DML4JXZ	Hemophilia	3B10.0	Phase 1	[3]
Eptacog alfa	DMAQYRL	Hemophilia	3B10.0	Phase 1	[6]
CB-813	DMXQGKL	Hemophilia	3B10.0	Phase 1	[7]
BAY 86-6150	DM6R3WC	Hemophilia	3B10.0	Discontinued in Phase 2/3	[8]
RNAPc2	DME9V0I	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[9]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[10]

Drug(s) Targeting Serum albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gadobenate Dimeglumine	DM4VAOG	Schizophrenia	6A20	Approved	[11]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[12]
Oxyphenbutazone	DMPZS7U	Arthritis	FA20	Approved	[13]
Iodipamide	DMXIQYS	Gallbladder disease	DC11.3	Approved	[14]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[15]
Gadofosveset	DM5V9U1	Imaging	QA0B	Approved	[16]
Albumin Human	DM5JTPU	Hypoalbuminemia	5C53.2	Approved	[17]
Bismuth	DMTKU46	Diarrhea	ME05.1	Approved	[18]
EVANS BLUE	DM5GT1M	Abdominal aortic aneurysm	BD50.4	Approved	[19]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor VII (F7)	TTF0EGX	FA7_HUMAN	Modulator	[2]
Serum albumin (ALB)	TTFNGC9	ALBU_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT02484638) Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors.
• [2] ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
• [4] Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.
• [5] Clinical pipeline report, company report or official report of Baxter.
• [6] Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121-36.
• [7] Clinical pipeline report, company report or official report of Catalyst Biosciences.
• [8] Bayer HealthCare and Maxygen Announce Hematology Agreement. U.S. Securities and Exchange Commission. July 2, 2008.
• [9] rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res. 2009 Jan 1;15(1):208-16.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [11] Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
• [12] Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.
• [13] Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
• [14] Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
• [15] Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
• [16] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [18] Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35.
• [19] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [20] Clinical pipeline report, company report or official report of Ablynx.